BioCentury | Nov 30, 2017
Emerging Company Profile

A versatile sponge

...to identify the causal pathogen and its products quickly enough to select a targeted therapy. Cellics Therapeutics Inc....
...the difference between persistent shock and sepsis resolution depends on removing all toxins, she added. Cellics’...
...incubator Arytha Biosciences LLC. Arytha spun out Cellics in 2014 to develop the RBC-coated nanosponges. Cellics...
BioCentury | Mar 1, 2004
Emerging Company Profile

Corporate Profile

T-cellic A/S Horsholm, Denmark Technology: T cell-guided localization and therapy Disease focus: Cancer Clinical status: Preclinical Founded: 2000 by Torsana A/S Corporate partners: NA University collaborators: Universities of Aarhus, Copenhagen and Berlin Number of employees:...
BioCentury | Mar 1, 2004
Emerging Company Profile

T-cellic: T cells deliver the goods

Knowing that the human immune system tries to mount a defense against cancer, some companies have attempted to harness or enhance immune responses as a minimally toxic treatment approach. T-cellic A/S instead uses the immune...
Items per page:
1 - 3 of 3
BioCentury | Nov 30, 2017
Emerging Company Profile

A versatile sponge

...to identify the causal pathogen and its products quickly enough to select a targeted therapy. Cellics Therapeutics Inc....
...the difference between persistent shock and sepsis resolution depends on removing all toxins, she added. Cellics’...
...incubator Arytha Biosciences LLC. Arytha spun out Cellics in 2014 to develop the RBC-coated nanosponges. Cellics...
BioCentury | Mar 1, 2004
Emerging Company Profile

Corporate Profile

T-cellic A/S Horsholm, Denmark Technology: T cell-guided localization and therapy Disease focus: Cancer Clinical status: Preclinical Founded: 2000 by Torsana A/S Corporate partners: NA University collaborators: Universities of Aarhus, Copenhagen and Berlin Number of employees:...
BioCentury | Mar 1, 2004
Emerging Company Profile

T-cellic: T cells deliver the goods

Knowing that the human immune system tries to mount a defense against cancer, some companies have attempted to harness or enhance immune responses as a minimally toxic treatment approach. T-cellic A/S instead uses the immune...
Items per page:
1 - 3 of 3